Are gene signatures better than traditional clinical factors?

The Lancet Oncology

Volumn 9, Issue 3, 2008, Pages 197-198

  Neven, Patrick ^a   Van Belle, Vanya ^a   Brouckaert, Olivier ^a   Pintens, Saskia ^a   Paridaens, Robert ^a   Christiaens, Marie Rose ^a   Deraedt, Karen ^a   Moerman, Philippe ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; VASCULOTROPIN;

BREAST CANCER; CANCER GENETICS; CANCER GRADING; CANCER RELAPSE; DNA MICROARRAY; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; BREAST TUMOR; CLASSIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; NOTE; PATHOLOGY; RISK ASSESSMENT;

BREAST NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RISK ASSESSMENT;

EID: 40749108535     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70047-0     Document Type: Letter

References (10)

1. Bueno-de-Mesquita J., van Harten W., Retel V., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8 (2007) 1079-1087
2. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
3. Robbins P., Pinder S., de Klerk N., et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26 (1995) 873-879
4. Lee A., Pinder S., Macmillan R., et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 42 (2006) 357-362
5. Callagy G., Pharoah P., Pinder S., et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12 (2006) 2468-2475
6. de Azambuja E., Cardoso F., de Castro Jr. G., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 96 (2007) 1504-1513
7. Coradini D., Boracchi P., Daidone M., et al. Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer 85 (2001) 795-797
8. Suen D., and Chow L. Prognostic contribution of the HER-2 oncogene overexpression to the Nottingham Prognostic Index in breast cancer. Biomed Pharmacother 60 (2006) 293-297
9. Ponzone R., Montemurro F., Maggiorotto F., et al. Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol 17 (2006) 1631-1636
10. Edén P., Ritz C., Rose C., Fernö M., and Peterson C. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40 (2004) 1837-1841